INS and type 1 diabetes mellitus: We compared clinical parameters between baseline and at 26–42 weeks of treatment, and intriguingly, in recent-onset T1D patients, we observed a significant increase in the fasting C-peptide level (P = .013) and a significant decrease in HbA1c (P = .003), fasting blood glucose (P = .033), and insulin/weight ratio (P = .028).